Biopharmaceutical company “FORT” – a joint asset of the holding “national immunobiological company” rostec state Corporation and Marathon Group – will open a research center to develop vaccines. The specialized complex is planned to put into operation in November 2020.
The new center will consist of four laboratories: cell technologies, microbiological, virological and PCR laboratory. The total area of the complex is more than 1000 square meters. Investment in the project will exceed 400 million rubles
“The creation of high-tech research center opens new avenues for research in this area. From 2021 on its basis it is planned to launch the site for the production of pilot series of new vaccines with subsequent scaling of production”, – said the Executive Director of Rostec Oleg Yevtushenko.
The Director of “FORT” Pavel Vandyshev said that the focus research center will be the development of live virus vaccines and vaccine prophylaxis of influenza, based on cellular technologies.